Table 1.

Anti-A549 cell IgG, IgM and IgA levels in SARS patient sera.

	% A549 cell binding (mean ± SD)
	IgG	IgM	IgA
Healthy controls (n = 10)	4·5 ± 1·5	5·2 ± 3·7	4·9 ± 2·3
SARS patients (Fever onset days)
Early (< 20 days)(n = 80)	5·8 ± 0·6	2·3 ± 1·1	2·6 ± 0·8
Late (≥ 20 days)(n = 41)	24·8 ± 15·5*†	6·4 ± 9·4	10·3 ± 9·2
Late
20–40 days (n = 18)	22·7 ± 15·6*†‡	8·0 ± 8·3	13·6 ± 13·3
41–61 days (n = 23)	22·6 ± 15·5*†	6·8 ± 12·4	9·1 ± 10·6
62–82 days (n = 14)	19·8 ± 10·2*†	4·2 ± 6·7	8·4 ± 4·9
> 82 days (n = 5)	16·9 ± 5·8*†	5·0 ± 1·8	6·5 ± 4·8
Pneumonia patients (n = 8)	8·9 ± 2·7	4·7 ± 2·3	2·2 ± 1·7

^*P < 0·001 versus healthy control

^†P < 0·001 versus early;

^‡P < 0·05 versus fever onset > 82 days.